With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Vitamin A–mediated targeting of small interfering (si)RNA to stellate cells reverses liver cirrhosis. You have full access to this article via your institution. This study is among the first to ...

Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...

Genetic, biochemical and structural studies have implicated Argonaute proteins as the catalytic core of the RNAi effector complex, RISC. Here we show that recombinant, human Argonaute2 can combine ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

In December 2025, Alnylam Pharmaceuticals announced a US$250 million expansion of its Norton, Massachusetts siRNA manufacturing facility and, together with PeptiDream, achieved a preclinical milestone ...

Two start-ups have launched to develop next-generation drugs using small interfering RNA (siRNA) to silence genes. The first, Judo Bio, is a spin-off of the venture capital firm Atlas Venture. The ...

SHANGHAI and SANTA BARBARA, Calif., /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides. The drugmaker is paying $85 million upfront to Empirico ...

In a study published in Cell Reports Physical Science on Nov. 25, a research team reported the development of an innovative intelligent light-guided biohybrid system, the CTPA/siCSF1R system, to ...

Transfecting siRNA with a high efficiency won’t be a challenge for you anymore thanks to these tips. siRNA transfection is a powerful tool to understand underlying mechanisms in gene regulation and ...